Home Tibial Nerve Stimulation for Bladder Urgency: What Sham Trials Found

Transcutaneous tibial nerve stimulation (TTNS) uses skin electrodes. Office-based percutaneous tibial nerve stimulation (PTNS) uses a needle near the ankle. Evidence for one arrangement does not automatically establish another device’s effectiveness.¹

What “80% success” meant in the sock trial

The 2022 ZIDA sock-device study² randomized 40 adults. Treatment was thirty minutes weekly for twelve weeks at home. Among those supplying final diaries, 16/20 using active treatment and 7/18 using sham met the success definition: 80% versus 39% (P=0.02).²

Success meant at least 50% fewer urgency-associated voids or at least 30% fewer daily voids. It did not require complete dryness. Two participants lacked final diaries. Exodus Innovations funded the study. Two active-treatment participants reported brief foot pain. Longer follow-up was needed to establish durability.²

The percentage is a responder rate under that definition, rather than the average reduction in leaks or proof that any electrode sock works.

The trial of 100 women did not show a clear advantage

The 2025 double-masked study³ randomized 100 women with urgency urinary incontinence: 65 to TTNS and 35 to sham. After twelve weeks, its published abstract reports nearly identical improvement in symptom-severity scores: 19.5 points with TTNS and 19.4 with sham (P=1.0).³

The share achieving at least a 50% reduction in urgency-leak episodes was 58.8% versus 41.7%, but that difference was not statistically significant (P=0.2). The findings do not show that nobody benefited. They show that the study did not establish an advantage over its sham comparison.³

A newer foot-electrode device improved a symptom score

A separate 2025 trial⁴ randomized 109 adults, including 85 women, to TNS-01 or sham. It used electrodes on the sole of the foot, with thirty-minute sessions three times weekly for twelve weeks, after initial instruction.⁴

The mean reduction in the 0-to-15 Overactive Bladder Symptom Score was 2.83 versus 1.62 points. The between-group difference was 1.21 points (95% CI 0.24–2.19). However, twelve-week changes in urinary frequency, night-time voids, urgency and quality of life were not significantly different between groups.⁴

That supports a benefit on the selected primary score, with narrower evidence for the individual symptoms a buyer might want to change. The paper lists a MedTecX-affiliated author, while declaring no funding.⁴

Compare the proposed device with the result you need

These studies tested different equipment and schedules. Their responder definitions also differ. An urgency-associated toilet visit, an episode of leakage and a questionnaire score are not interchangeable measures.

The US AUA/SUFU guideline lists TTNS among noninvasive options, while treating needle-based PTNS separately. It emphasizes shared decisions that consider benefit, adverse effects and treatment burden.¹ Our tibial-versus-sacral stimulation explainer describes the appointment and equipment differences.

Bring the exact device name to your clinician. Ask whether its trial matches your symptoms, who checks fit and use, which outcome will judge benefit and what maintenance would involve. A favorable trial of another device cannot supply those answers.

Chapter 9’s “Specialist options for urge leaks” in Laugh, Sneeze, Jump places nerve stimulation beside other bladder treatments. Its three-day bladder log can help distinguish toilet frequency from urgency and leaks before that conversation.